Education
About Us
Working with TipRanks
Follow Us
Cosmos Holdings Inc (COSM)
NASDAQ:COSM
Top Page
Cosmos Holdings
(NASDAQ:COSM)
Rating:49Neutral
Price Target:
$0.50
▲(4.17%Upside)
Cosmos Holdings (COSM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$13.39M
Dividend YieldN/A
Average Volume (3M)601.01K
Price to Earnings (P/E)―
Beta (1Y)1.82
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees149
SectorHealthcare
Sector Strength42
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding29,241,741
10 Day Avg. Volume222,190
30 Day Avg. Volume601,013
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)0.43
Price to Sales (P/S)0.00
P/FCF Ratio-2.06
Enterprise Value/Market Cap1.23
Enterprise Value/Revenue0.07
Enterprise Value/Gross Profit3.28
Enterprise Value/Ebitda-0.26
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Cosmos Holdings Business Overview & Revenue Model
Company DescriptionCosmos Holdings Inc. is a multinational healthcare group operating primarily in the pharmaceutical sector. The company focuses on the research, development, and distribution of pharmaceutical products, including branded and generic medicines, nutraceuticals, and over-the-counter products. With operations spanning various countries, Cosmos Holdings aims to improve health and wellness outcomes through an integrated approach to healthcare delivery.
How the Company Makes MoneyCosmos Holdings generates revenue primarily through the sale of its pharmaceutical products. The company's revenue model is centered around the distribution of branded and generic medications to pharmacies, hospitals, and clinics. In addition to its core pharmaceutical offerings, Cosmos Holdings also engages in the sale of nutraceuticals and other health-related products. Strategic partnerships with healthcare providers and distribution networks play a crucial role in broadening the company's market reach and enhancing its earnings potential. By leveraging its extensive distribution network and product portfolio, Cosmos Holdings continues to expand its presence in the global healthcare market.
Cosmos Holdings Financial Statement Overview
Summary
Cosmos Holdings faces significant financial hurdles with persistent net losses, shrinking revenue, and negative cash flows. While there are signs of reducing debt, the company's financial health remains strained by operational inefficiencies and a heavy reliance on liabilities. Sustainability and profitability improvements are essential to stabilize and enhance financial performance.Income Statement
Cosmos Holdings' income statement reveals challenges in profitability, with consistent net losses and negative EBIT and EBITDA margins over recent periods. The TTM data shows a slight reduction in revenue, indicating a -1.60% revenue growth rate compared to the previous annual period. Despite some improvement in gross profit margin over the TTM period, the negative net profit margin and declining revenue indicate struggles in operational efficiency and market position.45
Neutral
Balance Sheet
The balance sheet of Cosmos Holdings shows moderate financial stability with a debt-to-equity ratio stabilizing as stockholders' equity increases. However, high total liabilities and low equity ratios reflect potential solvency concerns. The company has reduced total debt significantly over the TTM period, but the equity ratio remains weak, indicating a heavy reliance on liabilities.50
Neutral
Cash Flow
Cosmos Holdings' cash flow statement highlights ongoing liquidity challenges, with negative free cash flow and operating cash flow over recent periods. The TTM shows a negative free cash flow growth rate of approximately 30.05% compared to the previous year, indicating inefficiencies in cash generation. The operating cash flow to net income ratio remains negative, underscoring persistent cash burn issues.40
Negative
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 53.55M | 54.43M | 53.38M | 50.35M | 56.24M | 55.41M | Gross Profit |
| 5.03M | 4.31M | 4.35M | 5.96M | 8.33M | 8.06M | EBIT |
| -14.54M | -15.54M | -21.83M | -7.47M | -4.53M | 2.71M | EBITDA |
| -12.52M | -13.92M | -17.06M | -8.90M | -3.82M | 3.18M | Net Income Common Stockholders |
| -15.13M | -16.18M | -18.54M | -13.83M | -7.96M | 820.79K |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 768.16K | 336.25K | 3.85M | 20.76M | 293.18K | 851.19K | Total Assets |
| 57.19M | 54.31M | 66.01M | 68.04M | 49.43M | 43.84M | Total Debt |
| 5.54M | 11.82M | 12.42M | 12.03M | 27.12M | 32.04M | Net Debt |
| 4.80M | 11.51M | 8.59M | -8.72M | 26.84M | 31.41M | Total Liabilities |
| 31.24M | 29.78M | 29.97M | 28.38M | 45.05M | 48.01M | Stockholders Equity |
| 25.95M | 24.53M | 36.04M | 39.66M | 4.38M | -4.16M |
| Cash Flow | Free Cash Flow | ||||
| -5.69M | -8.14M | -24.80M | -15.25M | -7.99M | -11.62M | Operating Cash Flow |
| -4.49M | -7.72M | -15.64M | -14.87M | -7.10M | -11.50M | Investing Cash Flow |
| -931.79K | -798.27K | -13.76M | -21.50K | -826.82K | -117.74K | Financing Cash Flow |
| 5.40M | 5.05M | 12.69M | 35.05M | 7.27M | 12.46M |
Cosmos Holdings Technical Analysis
Positive
0.48
Price Trends
0.42
Positive
0.52
Negative
0.67
Negative
Market Momentum
<0.01
Negative
58.38
Neutral
58.72
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COSM, the sentiment is Positive. The current price of 0.48 is above the 20-day moving average (MA) of 0.45, above the 50-day MA of 0.42, and below the 200-day MA of 0.67, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 58.38 is Neutral, neither overbought nor oversold. The STOCH value of 58.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for COSM.
Cosmos Holdings Risk Analysis
Cosmos Holdings disclosed 10 risk factors in its most recent earnings report. Cosmos Holdings reported the most risks in the “Legal & Regulatory” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cosmos Holdings Peers Comparison
Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $9.19M | ― | 3.29% | ― | -26.17% | ― | |
54 Neutral | $5.31B | 3.29 | -45.39% | 2.79% | 16.77% | -0.07% | |
49 Neutral | $13.39M | ― | -58.30% | ― | ― | ― | |
47 Neutral | $14.47M | ― | -7.72% | ― | 35.25% | 81.05% | |
45 Neutral | $5.67M | ― | -384.98% | ― | 14.27% | 87.31% | |
40 Neutral | $14.08M | ― | -336.65% | ― | -28.78% | 86.97% |
* Healthcare Sector Average
Performance Comparison
COSM
Cosmos Holdings
0.48
-0.15
-23.81%
TXMD
TherapeuticsMD
1.25
-0.83
-39.90%
AYTU
Aytu BioScience
2.00
-1.09
-35.28%
FLGC
Flora Growth
0.64
-0.51
-44.35%
BFRI
Biofrontera
0.60
-0.34
-36.17%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.